Fig. 5
Disease progression over time – (A) Baseline, (B) Faricimab 6 mg at 8 weeks, and (C) Follow-up at 6 months, switched to monthly Faricimab 12 mg regimen. Recurrence of subretinal fluid and no change in PED size can be observed
Fig. 5 | Scientific Reports
